The role of postchemotherapy surgery in managing metastatic germ cell tumors

Cancer

Volumn 110, Issue 12, 2007, Pages 2601-2603

  Beck, Stephen D W ^a  

^a Indiana Cancer Pavilion   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CISPLATIN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; GERM CELL TUMOR; HUMAN; LYMPH NODE DISSECTION; METASTASIS; MORBIDITY; NECROSIS; NON SEMINOMATOUS GERMINOMA; PATIENT SELECTION; PRIORITY JOURNAL; RETROPERITONEAL CANCER; TERATOMA; TREATMENT RESPONSE;

COMBINED MODALITY THERAPY; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; RETROPERITONEAL SPACE; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS;

EID: 37049039514     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23105     Document Type: Editorial

References (12)

1. Spiess PE, Tannir NM, Tu S-M, et al. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer. 2007;110:2700-2708.
2. Debono DJ, Heilman DK, Einhorn LH, Donohue Jp. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol. 1997;15:1455-1464.
3. Donohue JP, Foster RS. Management of retroperitoneal recurrences: seminoma and nonseminoma. Urol Clin North Am. 1994;21:761-772..
4. Carver BS, Stasi J, Bajorin D, Motzer RJ, Bosl GJ, Sheinfeld J. Improved clinical outcome for men with fibrosis at post chemotherapy retroperitoneal lymph node dissection for metastatic non-seminomatous germ cell tumors. J Urol. 2007;177:330. Abstract.
5. Vergouwe Y, Steyerberg EW, de Wit R, et al. External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. Br J Cancer. 2003;88:843-847.
6. Loehrer PJ Sr., Hui S, Clark S, et al. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. J Urol. 1986;135:1183-1189.
7. Stenning SP, Parkinson MC, Fisher C, et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer. 1998;83:1409-1419.
8. Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol. 2007;25:1033-1037.. Epub 2007 Jan 29.
9. Beck SDW, Foster RS, Bihrle R, Donohue JP, Einhorn LH. Long-term outcomes for patients with high volume retroperitoneal teratoma undergoing post chemotherapy surgery. J. Urol. 2007;177:331. Abstract.
10. Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy-results from an international study group. J Clin Oncol. 2001;19:2647-2657.
11. Einhorn LH, Williams SD, Mandelbaum I, Donohue JP. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer. 1981;48:904-908.
12. Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2005;23:6149-6156.